Beta-Blocker Use Is Associated With Impaired Left Atrial Function in Hypertension

Mayank Sardana1, Amer Ahmed Syed2, Zeba Hashmath2

  • 1Cardiology Division, Department of Medicine, University of Massachusetts Medical School, Worcester, MA.

Insights

Beta-blocker use in hypertension impairs left atrial (LA) mechanical function, affecting reservoir, conduit, and booster pump functions. This finding may explain increased risks of atrial fibrillation and stroke associated with beta-blockers.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Pharmacology

Background:

  • Impaired left atrial (LA) mechanical function is a known complication of hypertension.
  • The impact of different antihypertensive drug classes on LA function remains largely unknown.
  • LA dysfunction contributes to atrial arrhythmias, stroke, and heart failure.

Purpose of the Study:

  • To investigate the association between antihypertensive medication use and LA mechanical function in hypertensive patients.
  • To determine if specific antihypertensive drug classes differentially affect LA function.

Main Methods:

  • Cardiac MRI with feature-tracking was used to assess LA strain in 212 hypertensive subjects.
  • Multivariable regression models were employed to analyze associations, adjusting for relevant clinical and demographic factors.
  • LA function was evaluated based on reservoir, conduit, and booster pump capacities.

Main Results:

  • Beta-blocker use was significantly associated with impaired LA reservoir function (lower total longitudinal strain and expansion index).
  • Conduit function was also impaired in beta-blocker users (lower positive strain and early diastolic strain rate).
  • Booster pump function was reduced, indicated by lower late-diastolic strain/strain rate and active LA emptying fraction.

Conclusions:

  • Beta-blocker therapy is linked to impaired left atrial mechanical function in hypertension.
  • This association may contribute to the increased risk of atrial fibrillation and stroke observed with beta-blockers in recent studies.
  • Other antihypertensive agents did not show a significant association with impaired LA function.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.8K